Bioxyne Limited’s (ASX BXN: BXN), has said that its subsidiary Breathe Health Sciences (BLS), entered the German marijuana market in a multi-million dollar deal.
BLS signed a manufacturing and supply contract with German companies Farmakem d.o.o. Adrex Pharmaceuticals GmbH as the Buyer, and Adrex Pharmaceuticals GmbH an importer of, producer and distributor cannabis in Germany.
Farmakem and Adrex have agreed to purchase and distribute a minimum of 1,600kg of cannabis flower product manufactured by BLS during FY2026. Under this agreement, BLS expects to rack up a minimum of A$5.6m (€3.2m) in revenue over the next financial year. A first shipment of 580kg will be delivered in September and another for November.
Bioxyne has a strong growth outlook for FY2026. This is due to the expansion of their business in Australia, as well as entering new markets with high growth potential, such as Germany, UK, and other EU Countries. said the firm. In 2026, the German medical cannabis industry is predicted to grow rapidly after deregulation began in January 2025.
In a report published earlier this month, we stated that Germany’s medical cannabis imports in the first three months of 2019 were four times higher than the figures for the same time period in 2024. Imports from Australia during the period reached 804 kilograms, and 1.428 tonnes for the full year of 2024. This BLS transaction is more than Australia contributed for the entire year.
Bioxyne reports that Cannabis Flower is responsible for 95% of Germany’s medical cannabis sales. All products entering Germany are required to have GMP certification. As a GMP-certified manufacturer, BLS enjoys scale and cost benefits that will allow the company to gain significant business on German and European markets.
Bioxyne, in a similar vein, has announced that it received its Certificate of GMP Compliant with Europe Canada Singapore and United Kingdom.
The Company has been able to achieve certification in its efforts to grow globally with a particular focus on European and UK markets. stated the firm.
Bioxyne bought Breathe Life Sciences Pty Ltd. in May 2023. BLS is an Australian company founded in 2018 that has been licensed as a manufacturer, sponsor and to import and export controlled substances in Australia (S3,S4,S8).